Business

Amphastar Pharmaceuticals will pay Eli Lilly $500 million up front, an additional $125 million after one year, and up to $450 million in sales milestone payments for the rights to Baqsimi intranasal dry powder glucagon. The company says that the product is currently marketed in 27 countries. Baqsimi was approved by the FDA in July 2019 for the emergency treatment of … [Read more...] about Amphastar acquires Baqsimi intranasal dry powder glucagon from Lilly

Satsuma Pharmaceuticals, which was spun out of Shin Nippon Biomedical Laboratories (SNBL) over 6 years ago to develop an intranasal dry powder formulation of dihydroergotamine, has announced that it will now be acquired by SNBL. Satsuma recently said that it had submitted an NDA for STS101 DHE nasal powder for the treatment of migraine despite the failure of the Phase … [Read more...] about Satsuma Pharmaceuticals and its STS101 DHE nasal powder to be reacquired by SNBL

University of California, San Francisco spinout Aer Therapeutics has closed a $36 million Series A financing, with funds intended to support development of the company's AER-01 inhaled mucolytic for the treatment of COPD, the company said. According to the announcement, AER-01 is a thiol-saccharide designed to dissolve mucus plugs and was developed at UCSF in … [Read more...] about Aer Therapeutics closes $36 million financing to support development of AER-01 inhaled mucolytic for COPD

Tiziana Life Sciences has announced that the company will develop intranasal foralumab for the treatment of long COVID. In August 2021, Tiziana announced positive results from a pilot study of intranasal foralumab in mild-to-moderate COVID. The nasal formulation is currently in development for the treatment of non-active secondary progressive multiple sclerosis, and … [Read more...] about Tiziana says it will develop intranasal foralumab for the treatment of long COVID

According to Evoke Pharma, the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent that will protect the company's Gimoti metaclopramide nasal spray until 2030. The patent (No. 11628150, "Nasal Formulation of Metoclopramide") is expected to be issued on April 18, 2023. Other patents covering Gimoti include Nos. … [Read more...] about Evoke gets notice of allowance for additional US patent covering Gimoti metoclopramide nasal spray

DPI developer PureIMS announced that it has closed an investment round that included Boost-UP Foundation, CardusoCapital, IMDS Medical Devices, and LinesBridge Pharma Group, with funds intended mostly to support development of a levodopa DPI based on the company's Cyclops pre-filled single use dry powder inhaler. The amount of the new investment was not specified. … [Read more...] about PureIMS gets investment to fund development of its Levodopa Cyclops DPI